Physical and functional antagonism between tumor suppressor protein p53 and fortilin, an anti-apoptotic protein

Yanjie Chen, Takayuki Fujita, Di Zhang, Hung Doan, Decha Pinkaew, Zhihe Liu, Jiaxin Wu, Yuichi Koide, Andrew Chiu, Curtis Chen Jen Lin, Jui Yoa Chang, Ke He Ruan, Kenichi Fujise

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Tumor suppressor protein p53, our most critical defense against tumorigenesis, can be made powerless by mechanisms such as mutations and inhibitors. Fortilin, a 172-amino acid polypeptide with potent anti-apoptotic activity, is up-regulated in many human malignancies. However, the exact mechanism by which fortilin exerts its anti-apoptotic activity remains unknown. Here we present significant insight. Fortilin binds specifically to the sequence-specific DNA binding domain of p53. The interaction of fortilin with p53 blocks p53-induced transcriptional activation of Bax. In addition, fortilin, but not a double point mutant of fortilin lacking p53 binding, inhibits p53-dependent apoptosis. Furthermore, cells with wild-type p53 and fortilin, but not cells with wild-type p53 and the double point mutant of fortilin lacking p53 binding, fail to induce Bax gene and apoptosis, leading to the formation of large tumor in athymic mice. Our results suggest that fortilin is a novel p53-interacting molecule and p53 inhibitor and that it is a logical molecular target in cancer therapy.

Original languageEnglish (US)
Pages (from-to)32575-32585
Number of pages11
JournalJournal of Biological Chemistry
Volume286
Issue number37
DOIs
StatePublished - Sep 16 2011

Fingerprint

Tumor Suppressor Protein p53
Apoptosis Regulatory Proteins
Apoptosis
Tumors
Neoplasms
Genes
Chemical activation
Amino Acids
Nude Mice
Peptides
Transcriptional Activation
Molecules
DNA
Carcinogenesis
Mutation
Therapeutics

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology

Cite this

Physical and functional antagonism between tumor suppressor protein p53 and fortilin, an anti-apoptotic protein. / Chen, Yanjie; Fujita, Takayuki; Zhang, Di; Doan, Hung; Pinkaew, Decha; Liu, Zhihe; Wu, Jiaxin; Koide, Yuichi; Chiu, Andrew; Lin, Curtis Chen Jen; Chang, Jui Yoa; Ruan, Ke He; Fujise, Kenichi.

In: Journal of Biological Chemistry, Vol. 286, No. 37, 16.09.2011, p. 32575-32585.

Research output: Contribution to journalArticle

Chen, Y, Fujita, T, Zhang, D, Doan, H, Pinkaew, D, Liu, Z, Wu, J, Koide, Y, Chiu, A, Lin, CCJ, Chang, JY, Ruan, KH & Fujise, K 2011, 'Physical and functional antagonism between tumor suppressor protein p53 and fortilin, an anti-apoptotic protein', Journal of Biological Chemistry, vol. 286, no. 37, pp. 32575-32585. https://doi.org/10.1074/jbc.M110.217836
Chen, Yanjie ; Fujita, Takayuki ; Zhang, Di ; Doan, Hung ; Pinkaew, Decha ; Liu, Zhihe ; Wu, Jiaxin ; Koide, Yuichi ; Chiu, Andrew ; Lin, Curtis Chen Jen ; Chang, Jui Yoa ; Ruan, Ke He ; Fujise, Kenichi. / Physical and functional antagonism between tumor suppressor protein p53 and fortilin, an anti-apoptotic protein. In: Journal of Biological Chemistry. 2011 ; Vol. 286, No. 37. pp. 32575-32585.
@article{b6d05d5eaaeb41fcadca254e5fff4d7d,
title = "Physical and functional antagonism between tumor suppressor protein p53 and fortilin, an anti-apoptotic protein",
abstract = "Tumor suppressor protein p53, our most critical defense against tumorigenesis, can be made powerless by mechanisms such as mutations and inhibitors. Fortilin, a 172-amino acid polypeptide with potent anti-apoptotic activity, is up-regulated in many human malignancies. However, the exact mechanism by which fortilin exerts its anti-apoptotic activity remains unknown. Here we present significant insight. Fortilin binds specifically to the sequence-specific DNA binding domain of p53. The interaction of fortilin with p53 blocks p53-induced transcriptional activation of Bax. In addition, fortilin, but not a double point mutant of fortilin lacking p53 binding, inhibits p53-dependent apoptosis. Furthermore, cells with wild-type p53 and fortilin, but not cells with wild-type p53 and the double point mutant of fortilin lacking p53 binding, fail to induce Bax gene and apoptosis, leading to the formation of large tumor in athymic mice. Our results suggest that fortilin is a novel p53-interacting molecule and p53 inhibitor and that it is a logical molecular target in cancer therapy.",
author = "Yanjie Chen and Takayuki Fujita and Di Zhang and Hung Doan and Decha Pinkaew and Zhihe Liu and Jiaxin Wu and Yuichi Koide and Andrew Chiu and Lin, {Curtis Chen Jen} and Chang, {Jui Yoa} and Ruan, {Ke He} and Kenichi Fujise",
year = "2011",
month = "9",
day = "16",
doi = "10.1074/jbc.M110.217836",
language = "English (US)",
volume = "286",
pages = "32575--32585",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "37",

}

TY - JOUR

T1 - Physical and functional antagonism between tumor suppressor protein p53 and fortilin, an anti-apoptotic protein

AU - Chen, Yanjie

AU - Fujita, Takayuki

AU - Zhang, Di

AU - Doan, Hung

AU - Pinkaew, Decha

AU - Liu, Zhihe

AU - Wu, Jiaxin

AU - Koide, Yuichi

AU - Chiu, Andrew

AU - Lin, Curtis Chen Jen

AU - Chang, Jui Yoa

AU - Ruan, Ke He

AU - Fujise, Kenichi

PY - 2011/9/16

Y1 - 2011/9/16

N2 - Tumor suppressor protein p53, our most critical defense against tumorigenesis, can be made powerless by mechanisms such as mutations and inhibitors. Fortilin, a 172-amino acid polypeptide with potent anti-apoptotic activity, is up-regulated in many human malignancies. However, the exact mechanism by which fortilin exerts its anti-apoptotic activity remains unknown. Here we present significant insight. Fortilin binds specifically to the sequence-specific DNA binding domain of p53. The interaction of fortilin with p53 blocks p53-induced transcriptional activation of Bax. In addition, fortilin, but not a double point mutant of fortilin lacking p53 binding, inhibits p53-dependent apoptosis. Furthermore, cells with wild-type p53 and fortilin, but not cells with wild-type p53 and the double point mutant of fortilin lacking p53 binding, fail to induce Bax gene and apoptosis, leading to the formation of large tumor in athymic mice. Our results suggest that fortilin is a novel p53-interacting molecule and p53 inhibitor and that it is a logical molecular target in cancer therapy.

AB - Tumor suppressor protein p53, our most critical defense against tumorigenesis, can be made powerless by mechanisms such as mutations and inhibitors. Fortilin, a 172-amino acid polypeptide with potent anti-apoptotic activity, is up-regulated in many human malignancies. However, the exact mechanism by which fortilin exerts its anti-apoptotic activity remains unknown. Here we present significant insight. Fortilin binds specifically to the sequence-specific DNA binding domain of p53. The interaction of fortilin with p53 blocks p53-induced transcriptional activation of Bax. In addition, fortilin, but not a double point mutant of fortilin lacking p53 binding, inhibits p53-dependent apoptosis. Furthermore, cells with wild-type p53 and fortilin, but not cells with wild-type p53 and the double point mutant of fortilin lacking p53 binding, fail to induce Bax gene and apoptosis, leading to the formation of large tumor in athymic mice. Our results suggest that fortilin is a novel p53-interacting molecule and p53 inhibitor and that it is a logical molecular target in cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=80052740794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052740794&partnerID=8YFLogxK

U2 - 10.1074/jbc.M110.217836

DO - 10.1074/jbc.M110.217836

M3 - Article

VL - 286

SP - 32575

EP - 32585

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 37

ER -